Results 81 to 90 of about 6,213 (108)

Nelarabine: A novel purine antimetabolite antineoplastic agent

Clinical Therapeutics, 2007
Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.This article reviews the pharmacology, mechanism of action, and ...
Larry W, Buie, Stacy S, Epstein, Celeste M, Lindley   +2 more
openaire   +2 more sources

Intercalator-induced, toposiomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites

International Journal of Radiation Oncology*Biology*Physics, 1986
Defining specific biochemical targets of active antineoplastic agents could aid in discovering better anticancer therapy and more thoroughly understanding the biochemical basis of malignancy. Through a series of cellular and biochemical studies, we and others have identified the nuclear enzyme topoisomerase II as the target of several active agents ...
L A, Zwelling, L, Silberman, E, Estey
openaire   +2 more sources

Glycolysis-dependent antimetabolites: Possible improvement in antineoplastic selectivity

Medical Hypotheses, 1979
The increased rate of glycolysis in neoplastic cells may be used to design tentatively antimetabolites whose detoxification would be faster in normal cells. Pyruvo-substituted nucleotides are examined in this respect and their expected differential metabolism outlined.
openaire   +2 more sources

Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays

Cancer Chemotherapy and Pharmacology, 1989
The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed.
openaire   +2 more sources

[5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite].

Schweizerische medizinische Wochenschrift, 1980
5'-deoxy-5-fluorouridine (5-DFUR) exerts a marked cytostatic activity, both intraperitoneally and orally, against experimental tumors. It has a strong antitumor effect on the Crocker sarcoma S 180, the Lewis lung carcinoma and a chemically induced squamous cell carcinoma of the skin. Its ratio of antitumor activity toxicity is more favourable than that
H R, Hartmann, W, Bollag
openaire   +1 more source

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

Circulation Research, 2021
Karla Bianca Neves, R H J Mathijssen
exaly  

Melatonin’s Antineoplastic Potential Against Glioblastoma

Cells, 2020
Gaia Favero, Enrico Moretti, Rita Rezzani   +2 more
exaly  

[Comparison of the effects of alkylating agents, antimetabolites and antineoplastic agents of other types on hemopoietic CFU in mice].

Bollettino della Societa italiana di biologia sperimentale, 1976
G, Massa, A, Saviane, G, Bogliolo, I, Pannacciulli   +3 more
openaire   +1 more source

The Dolastatins, A Family of Promising Antineoplastic Agents

Current Pharmaceutical Design, 1999
Joel Poncet
exaly  

Further antineoplastic terpenylquinones and terpenylhydroquinones

Bioorganic and Medicinal Chemistry, 1998
Arturo San Feliciano Martín, Marina Gordaliza, M A Castro   +2 more
exaly